Literature DB >> 26156804

Speckle-type POZ protein is negatively associated with malignancies and inhibits cell proliferation and migration in liver cancer.

Yuping Huang1, Ning Tan2, Deshui Jia3, Ying Jing1, Qifeng Wang3, Zhe Li3, Jiwei Zhang3, Li Liu3, Jinjun Li1, Zhiao Chen4, Xianghuo He5,6.   

Abstract

Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor that is frequently mutated in human cancers. Our previous findings have indicated that SPOP is mutated and functions as a novel tumor suppressor in hepatoblastoma (HB). However, the biological roles and clinical significance of this SPOP in hepatocellular carcinoma (HCC) remain unknown. In this study, we found that the expression level of SPOP was downregulated in HCC primary tumors by quantitative real-time PCR and the protein level of SPOP was also reduced in 72 pairs of HCC tissue microarrays by immunohistochemical analyses. Moreover, SPOP expression was observed to negatively correlate with the tumor grade and intrahepatic metastasis of HCC patients. Furthermore, we revealed that SPOP not only inhibits cell proliferation but also inhibits the motility of liver cancer cells. Finally, we discovered that one of the mechanisms through which SPOP inhibits liver cancer cell migration involves the disruption of ZEB2 expression and the associated epithelial-mesenchymal transition program. Together, our findings emphasize the critical role of SPOP in the regulation of proliferation and migration in liver cancer.

Entities:  

Keywords:  Epithelial-mesenchymal transition; Liver cancer; SPOP; Tumor suppressor

Mesh:

Substances:

Year:  2015        PMID: 26156804     DOI: 10.1007/s13277-015-3753-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification.

Authors:  B Orsetti; F Courjal; M Cuny; C Rodriguez; C Theillet
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Fold prediction and evolutionary analysis of the POZ domain: structural and evolutionary relationship with the potassium channel tetramerization domain.

Authors:  L Aravind; E V Koonin
Journal:  J Mol Biol       Date:  1999-01-29       Impact factor: 5.469

4.  Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.

Authors:  Jean-Philippe P Theurillat; Namrata D Udeshi; Wesley J Errington; Tanya Svinkina; Sylvan C Baca; Marius Pop; Peter J Wild; Mirjam Blattner; Anna C Groner; Mark A Rubin; Holger Moch; Gilbert G Prive; Steven A Carr; Levi A Garraway
Journal:  Science       Date:  2014-10-02       Impact factor: 47.728

5.  Identification of a novel nuclear speckle-type protein, SPOP.

Authors:  Y Nagai; T Kojima; Y Muro; T Hachiya; Y Nishizawa; T Wakabayashi; M Hagiwara
Journal:  FEBS Lett       Date:  1997-11-24       Impact factor: 4.124

6.  Diverse somatic mutation patterns and pathway alterations in human cancers.

Authors:  Zhengyan Kan; Bijay S Jaiswal; Jeremy Stinson; Vasantharajan Janakiraman; Deepali Bhatt; Howard M Stern; Peng Yue; Peter M Haverty; Richard Bourgon; Jianbiao Zheng; Martin Moorhead; Subhra Chaudhuri; Lynn P Tomsho; Brock A Peters; Kanan Pujara; Shaun Cordes; David P Davis; Victoria E H Carlton; Wenlin Yuan; Li Li; Weiru Wang; Charles Eigenbrot; Joshua S Kaminker; David A Eberhard; Paul Waring; Stephan C Schuster; Zora Modrusan; Zemin Zhang; David Stokoe; Frederic J de Sauvage; Malek Faham; Somasekar Seshagiri
Journal:  Nature       Date:  2010-07-28       Impact factor: 49.962

7.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.

Authors:  Chuandong Geng; Bin He; Limei Xu; Christopher E Barbieri; Vijay Kumar Eedunuri; Sue Anne Chew; Martin Zimmermann; Richard Bond; John Shou; Chao Li; Mirjam Blattner; David M Lonard; Francesca Demichelis; Cristian Coarfa; Mark A Rubin; Pengbo Zhou; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-04       Impact factor: 11.205

8.  BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase.

Authors:  Jeong Eun Kwon; Muhnho La; Kyu Hee Oh; Young Mi Oh; Gi Ryang Kim; Jae Hong Seol; Sung Hee Baek; Tomoki Chiba; Keiji Tanaka; Ok Sun Bang; Cheol O Joe; Chin Ha Chung
Journal:  J Biol Chem       Date:  2006-03-08       Impact factor: 5.157

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.

Authors:  Zhiao Chen; Xinyuan Lu; Zhichao Wang; Guangzhi Jin; Qifeng Wang; Di Chen; Taoyang Chen; Jinjun Li; Jia Fan; Wenming Cong; Qiang Gao; Xianghuo He
Journal:  Oncotarget       Date:  2015-02-10
View more
  11 in total

Review 1.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

Review 2.  The roles of E3 ligases in Hepatocellular carcinoma.

Authors:  Zongdong Yu; Hong Li; Jie Zhu; Haibiao Wang; Xiaofeng Jin
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 3.  SPOP and cancer: a systematic review.

Authors:  Alison Clark; Marieke Burleson
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

4.  [Speckle-type POZ protein up-regulates c-Jun protein expression and promotes proliferation and invasion of renal carcinoma cells].

Authors:  L Wu; K Yu; Y Cue; X Zhu; Z Yang; J Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-03-25

5.  Speckle-Type POZ Protein Down-Regulates Matrix Metalloproteinase 2 Expression via Sp1/PI3K/Akt Signaling Pathway in Colorectal Cancer.

Authors:  Shouhua Zhang; Juhua Xiao; Yong Chai; Zhengdong Hong; Zhiqiang Liu; Rongfa Yuan; Zhipeng Luo; Xin Zhou; Don Eliseo Lucero-Prisno; Kai Huang
Journal:  Dig Dis Sci       Date:  2017-12-19       Impact factor: 3.487

6.  GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.

Authors:  Yihua Pei; Qin Yao; Sibo Yuan; Bozhen Xie; Yan Liu; Chunsheng Ye; Huiqin Zhuo
Journal:  Oncotarget       Date:  2016-11-22

7.  miRNA-543 promotes cell migration and invasion by targeting SPOP in gastric cancer.

Authors:  Junfei Xu; Feiran Wang; Xi Wang; Zhixian He; Xinguo Zhu
Journal:  Onco Targets Ther       Date:  2018-08-21       Impact factor: 4.147

8.  RNA interference-mediated silencing of speckle-type POZ protein promotes apoptosis of renal cell cancer cells.

Authors:  Xiaoxia Liu; Guiling Sun; Xiuju Sun
Journal:  Onco Targets Ther       Date:  2016-04-20       Impact factor: 4.147

Review 9.  Functional roles of Speckle-Type Poz (SPOP) Protein in Genomic stability.

Authors:  Xi Wei; Joshua Fried; Ying Li; Linfei Hu; Ming Gao; Sheng Zhang; Bo Xu
Journal:  J Cancer       Date:  2018-09-07       Impact factor: 4.207

10.  SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG.

Authors:  Peng Tan; Yunke Xu; Yichao Du; Lile Wu; Bing Guo; Shiyao Huang; Jinhui Zhu; Bo Li; Fujun Lin; Lei Yao
Journal:  Cell Death Dis       Date:  2019-10-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.